Vietnam has signed contracts with Russia, the United States and Japan to transfer COVID19 vaccine technologies, said Nguyễn Ngô Quang, deputy director of science, technology and education at the Ministry of Health. According to the official, one of the three companies has been sealed between two Vietnamese companies, Vaccine and Biological Products Company No. 1 (VABIOTECH) and International Progressive Joint Stock Company (AIC) and Japanese pharmaceutical company Shionogi. VABIOTECH, a state-owned company dependent on the Ministry of Health, is one of the leading entities in the research, manufacture and sale of vaccines and biological products for human use in the country Protein SARSCoV2, a baculovirus expression vector system, the parties sign a confidentiality agreement for access to vaccine and technology In relation to the technology transfer project between AIC and Shionogi, the Ministry of Health has signed a cooperation and is preparing a plan for the implementation of the third phase of clinical studies in Vietnam (via the National Institute of Hygiene and Epidemiology) and procedures for the technology transfer (via VABIOTECH) The vaccine is expected to be completed and in VABIOTECH, DSBio and the Russian Direct Investment Fund with the Vietnamese party in charge of packaging the vaccine tubes of the products. half-finished cough. to Russia for quality control. After the completion of the relevant tests on August 10, the tubes of the SputnikV vaccine will be produced under the contract in a quantity of 5 million doses per month.It would start with 500,000 doses in August and then scale to 100 million doses a year. For the technology transfer project with US partners, the Department of Health has sent a group of experts to coordinate with the World Health Organization (WHO) to assist units in preparing dossiers for clinical trials in a shortened manner, and the investigation is expected to begin on August 1 End at the end of December. VinBiocare is reportedly in negotiations with Arcturus Therapeutics, the maker of a COVID19 mRNA, for phase 3 studies in Vietnam and subsequent production. The relocation and construction of a vaccine factory in Vietnam will be completed in June 2022.